1. Background
CV Therapeutics, Inc. which was founded in the year 19911, is the company of biopharmaceutical based in California in Palo Alto. The company has employees ranging from 200 to 500. The company is involved in the development, discovery and commercialization of the drugs for treatment of diseases. The company utilizes advances registered in genetics and molecular biology to detect mechanisms of the cardiovascular diseases, as well as targeting the discovery of drugs. In addition, the company is specifically involved in the development of angina pectoris. The CV Therapeutics operates in the United States of America under the industry of healthcare. The CV Therapeutics, being Biopharmaceutical Company, which is research oriented, it …show more content…
It is costly to research and develop drugs as there exist requirements and regulations that are strict, and have to be followed in many countries. However, the studies done on the pharmaceutical companies reveals ethical concerns that warrant attention. For instance, marketing priorities and practices of pharmaceutical companies have been scrutinized heavily for several years. There appears that pharmaceutical companies are emphasizing more on the drugs fitting scare mongering, as well as problems that are over medicalized. Thorough testing and clinical trials are essential to have medical drugs that are good, but it seems there are several shortcuts that comprise of pressuring to have results which are favorable, carrying tests on people minus their consent, as well as applying drugs for uses that are not approved (Cavusgil et al., 2014; Shah, …show more content…
The studies conducted in oversees especially on newly developed drugs goes faster, since the companies find it easy to locate participants who are eager to take part in the clinical trials and testing. The company was faced with the ethical challenge as the clinical trials and testing approached termination stages, whether to ensure the drug is easily accessed by the patients living in countries that are poor, who participated in the clinical trials. Since there are several companies that are conducting tests of new drugs they have developed in the other nations, they are faced with the challenge of whether they have a responsibility to take care of the people who participated in clinical trials, or not. There are some pharmaceutical companies that prefer not to make their drugs available in countries which participated in testing of developed drugs (Emanuel et al.,
CV Therapeutics, Inc. which was founded in the year 19911, is the company of biopharmaceutical based in California in Palo Alto. The company has employees ranging from 200 to 500. The company is involved in the development, discovery and commercialization of the drugs for treatment of diseases. The company utilizes advances registered in genetics and molecular biology to detect mechanisms of the cardiovascular diseases, as well as targeting the discovery of drugs. In addition, the company is specifically involved in the development of angina pectoris. The CV Therapeutics operates in the United States of America under the industry of healthcare. The CV Therapeutics, being Biopharmaceutical Company, which is research oriented, it …show more content…
It is costly to research and develop drugs as there exist requirements and regulations that are strict, and have to be followed in many countries. However, the studies done on the pharmaceutical companies reveals ethical concerns that warrant attention. For instance, marketing priorities and practices of pharmaceutical companies have been scrutinized heavily for several years. There appears that pharmaceutical companies are emphasizing more on the drugs fitting scare mongering, as well as problems that are over medicalized. Thorough testing and clinical trials are essential to have medical drugs that are good, but it seems there are several shortcuts that comprise of pressuring to have results which are favorable, carrying tests on people minus their consent, as well as applying drugs for uses that are not approved (Cavusgil et al., 2014; Shah, …show more content…
The studies conducted in oversees especially on newly developed drugs goes faster, since the companies find it easy to locate participants who are eager to take part in the clinical trials and testing. The company was faced with the ethical challenge as the clinical trials and testing approached termination stages, whether to ensure the drug is easily accessed by the patients living in countries that are poor, who participated in the clinical trials. Since there are several companies that are conducting tests of new drugs they have developed in the other nations, they are faced with the challenge of whether they have a responsibility to take care of the people who participated in clinical trials, or not. There are some pharmaceutical companies that prefer not to make their drugs available in countries which participated in testing of developed drugs (Emanuel et al.,